Cyrus K. Mirsaidi Announced as President and CEO of Formex
San Diego, CA – February 17, 2015 – Biotech Investment Group (BIG), a privately held investment fund and provider of growth capital to emerging healthcare services companies, announced today the appointment of Cyrus K. Mirsaidi, to President and CEO of Formex, LLC. Formex is a BIG portfolio company, and a leader in pharmaceutical API formulation, development and cGMP manufacturing, with a turnkey 40,000 sf manufacturing facility in Torrey Pines, San Diego. Mr. Mirsaidi, who has served as CEO of Molecular Response, LLC (MRL), a San Diego-based translational oncology services company from its inception in 2010, will continue to serve on its board as Vice Chairman and acting CEO. Molecular Response will continue to work closely with pharmaceutical partners.
Mr. Mirsaidi will directly report to Dr. Masood Tayebi, the Chairman of the Board for both BIG and Formex. Mr. Mirsaidi will lead Formex’s overall strategy and more specifically focus on corporate expansion, process improvements and excellence across all operational areas.
“Cyrus has been a key contributor to BIG portfolio companies for several years, and has proven himself as a strong and capable leader,” said Chairman, Dr. Masood Tayebi. “At BIG, we are focused on identifying healthcare companies in need of growth capital and management expertise. Cyrus’ leadership of Formex will build on current platform and established expertise in formulation and analytical development and enable BIG to realize the full potential of unique cGMP offerings in pre-clinical to phase 3 drug development and manufacturing.”
Mr. Mirsaidi brings both practical and strategic senior management experience for young start-ups to fortune 100 companies, with proven track record from FDA regulated clinical diagnostics to high throughput compound library synthesis and purification, and from pre-clinical drug development, to clinical programs for targeted therapeutics in translational oncology. He held several senior level management positions in his ten-year career at Nichols Institute Diagnostics (a division of Quest Diagnostics), where he was responsible for global launch of FDA regulated, clinical diagnostic IVD tests and automated platforms. As general manager and executive director at Ontogen, a small molecule discovery company, he managed operations of a subsidiary focused on high throughput synthesis and purification of novel chemical compounds. Mr. Mirsaidi served as Vice President at AltheaDx, a spin-out from Althea Technologies, a San Diego biologics GMP manufacturing company, and most recently served as CEO and founder of Molecular Response, LLC, a CRO focused on translational oncology.